LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
LISATA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.00−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $9.11M
- P/E (TTM)
- –
- Dividend yield
- –
LISATA THERAPEUTICS, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q1 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $0 | – | – | – | $70.00K | – | – | – | – | – | – | – | – | -100.0% |
| R&D Segment [Member] | – | – | – | – | – | – | – | – | – | – | – | $0 | – | – |
| PCT Segment [Member] | – | – | – | – | – | – | – | – | – | – | – | $7.92M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q1 17 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | -$3.99M | -$4.94M | -$3.08M | -$4.41M | -$4.87M | -$5.85M | -$4.95M | -$5.34M | -$5.52M | -$6.60M | – | – | -18.0% |
| R&D Segment [Member] | – | – | – | – | – | – | – | – | – | – | – | -$7.74M | – |
| PCT Segment [Member] | – | – | – | – | – | – | – | – | – | – | – | -$1.80M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Lisata Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.